Aurobindo Pharma receives EIR
Aurobindo Pharma receives EIR

Aurobindo Pharma receives EIR

Geyatee Deshpande Article rating: 3.3

Aurobindo Pharma announced of receiving an Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from USFDA for its Hyderabad facility.

RBI lifts ban on Bandhan Bank; stock rise
RBI lifts ban on Bandhan Bank; stock rise

RBI lifts ban on Bandhan Bank; stock rise

Avalokita Pandey Article rating: 3.9

Bandhan Bank’s current promoter holding is still above the mandated level, that is, at 61 per cent, however, despite this, RBI removed its restriction on the pretext of ‘considering the efforts made by Bandhan Bank to comply with the said licensing condition.’

USFDA flags Ciplas Goa facility
USFDA flags Ciplas Goa facility

USFDA flags Ciplas Goa facility

Geyatee Deshpande Article rating: 4.8

Pharma major Cipla reported to the exchanges that United States Food and Drug Administration (USFDA) have issued a warning letter in accordance with the inspection held at the company’s manufacturing facility in Goa.

Index trend and stocks in action on February 26, 2020
Index trend and stocks in action on February 26, 2020

Index trend and stocks in action on February 26, 2020

Karan Dsij Article rating: 5.0

Overall, the structure is weak for the short-term and rallies are likely to be sold until the resistance zone of 11,900-11,930 is not crossed. Stocks in news: IRB Infrastructure Developers, Bandhan Bank, Bank of Baroda, Godawari Power & Ispat, Arrow Greentech.

Bears likely to continue their dominance
Bears likely to continue their dominance

Bears likely to continue their dominance

Karan Dsij Article rating: 4.3

The colossal sell-off overnight on Wall Street as Centres for Disease Control (CDC) officials called the spread of Coronavirus in United States inevitable and this has triggered a negative sentiment in Asian markets as well. Early action at SGX Nifty is indicating a worrisome sign ahead for Indian markets as there are chances that we might open with a big gap down.

Shares of Indigo down post SEBI report on RPTs
Shares of Indigo down post SEBI report on RPTs

Shares of Indigo down post SEBI report on RPTs

Avalokita Pandey Article rating: 5.0

Besides, an official statement issued by Sanjay Gupta, Company Secretary & Chief Compliance Officer at InterGlobe Aviation states that the report is factually incorrect and the company has not received any communication from SEBI in this regard.

Lupin launch tablets for treatment of Edema
Lupin launch tablets for treatment of Edema

Lupin launch tablets for treatment of Edema

Geyatee Deshpande Article rating: 3.3

Lupin announced the launch of Ethacrynic Acid Tablets USP, 25 mg used for the treatment of Edema. The pharma major had already received an approval from United States Food and Drug Administration (USFDA) earlier for this drug.

Checks to perform before investing in bank FD
Checks to perform before investing in bank FD

Checks to perform before investing in bank FD

Henil Shah Article rating: 5.0

Fixed deposits are one of the most popular fixed income investments among retail investors. Having said that, what are the checks that investors should perform before investing in bank FDs? Let’s find out!

Havells India forms triple bottom pattern
Havells India forms triple bottom pattern

Havells India forms triple bottom pattern

Vinayak Gangule Article rating: 4.6

On Tuesday, the stock has given a neckline breakout of triple bottom pattern. This breakout was confirmed by above 50-day average volumes. 

Navin Fluorine jumps 20 per cent on multi-year deal
Navin Fluorine jumps 20 per cent on multi-year deal

Navin Fluorine jumps 20 per cent on multi-year deal

Nidhi Jani Article rating: 4.7

The capex and project will be executed through its wholly-owned subsidiary, Navin Fluorine Advanced Sciences Limited (NFASL). It will invest around USD 51.5 million for setting up dedicated manufacturing facility and USD 10 million for setting up captive power plant.

RSS
First28802881288228832885288728882889Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR